U.S. markets closed
  • S&P 500

    3,911.74
    +116.01 (+3.06%)
     
  • Dow 30

    31,500.68
    +823.32 (+2.68%)
     
  • Nasdaq

    11,607.62
    +375.43 (+3.34%)
     
  • Russell 2000

    1,765.74
    +54.06 (+3.16%)
     
  • Crude Oil

    107.06
    +2.79 (+2.68%)
     
  • Gold

    1,828.10
    -1.70 (-0.09%)
     
  • Silver

    21.13
    +0.09 (+0.42%)
     
  • EUR/USD

    1.0559
    +0.0034 (+0.33%)
     
  • 10-Yr Bond

    3.1250
    +0.0570 (+1.86%)
     
  • GBP/USD

    1.2270
    +0.0009 (+0.07%)
     
  • USD/JPY

    135.2100
    +0.2770 (+0.21%)
     
  • BTC-USD

    21,296.25
    +247.36 (+1.18%)
     
  • CMC Crypto 200

    462.12
    +8.22 (+1.81%)
     
  • FTSE 100

    7,208.81
    +188.36 (+2.68%)
     
  • Nikkei 225

    26,491.97
    +320.72 (+1.23%)
     

Bayer Intends To Bow Out From CAR-T Therapy Pact With Atara

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Atara Biotherapeutics Inc (NASDAQ: ATRA) received notification that Bayer AG's (OTC: BAYRYintends to end the exclusive worldwide licensing agreement for mesothelin-directed CAR T-cell therapies.

  • The collaboration included the funding and development of ATA3271, allogeneic T-cell immunotherapy, and an autologous version, ATA2271, for high mesothelin-expressing tumors.

  • ATA3271 leverages Atara's EBV T-cell platform and is currently in IND (Investigational New Drug)-enabling studies.

  • Related: Atara Biotherapeutics Shares Fall After Reporting Patient Death In ATA2271 Autologous CAR T Trial.

  • Upon termination of the agreement in September 2022, Atara will have full rights to continue the clinical development and future commercialization of its programs worldwide.

  • Atara expects to provide a Phase 1 data update for ATA2271 in H2 2022 and will also continue to lead IND-enabling studies and process development for ATA3271.

  • "Given the exciting developments on ATA188 and tab-cel and our continued progress toward submitting an IND for ATA3219 in Q4 2022, we plan to focus our resources accordingly while re-assess our strategy for our mesothelin CAR T program," said Pascal Touchon, President and CEO of Atara.

  • "Consequently, we will postpone the anticipated IND filing for ATA3271 beyond the fourth quarter of 2022. We are also maintaining our cash runway guidance into Q4 of 2023," Touchon added.

  • Price Action: ATRA shares closed 14.3% lower at $4.42 during after-hours trading on Thursday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.